PTX-100 reduced multiple myeloma tumours AND sensitised multiple myeloma cells in mice models.
Should see buyers return to the stock as the data is presented today at the Cancer Research Meeting.
EV value of $2M is absurd given the trials both pending and underway.
Even at 16c the stock would still be cheap compared to its ASX peers.
Cheers.
.
